---
title: "The Latest on Align's Buyback, BNY Mellon's Crypto Push, and More"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295518243.md"
description: "Amid broader market fluctuations, companies from medical devices to finance are reassessing strategies for late 2026. Here is a look at the latest internal moves at Align, Solid Power, BNY Mellon, and others."
datetime: "2026-08-11T10:12:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295518243.md)
  - [en](https://longbridge.com/en/news/295518243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295518243.md)
generator: "portal-rs"
---

# The Latest on Align's Buyback, BNY Mellon's Crypto Push, and More

I'm told that against a backdrop of increasing market volatility, several companies across varied sectors are quietly preparing for strategic overhauls and internal realignments. According to people familiar with the matter, management teams from medical device makers to legacy financial institutions are heavily reassessing their capital allocation plans for the second half of 2026. This is the most significant strategic shift for this group since earlier this year.

### Align Technology (ALGN.US)

The maker of Invisalign has seen its shares pull back significantly this year. I've learned that following a Q2 2026 earnings miss—with EPS coming in at USD 1.52—the company quickly initiated a comprehensive strategic review. In late July, Align not only announced the appointment of three new independent directors but also committed to a USD 400 million to USD 500 million stock buyback this year. Management hopes this will solidify its dominant market share after a major rival exited the space.

### Solid Power (SLDP.US)

Solid Power's stock experienced some turbulence following its Q2 2026 results. Even though quarterly revenue briefly turned negative due to a USD 1.2 million non-cash write-off and operating losses hit USD 30.3 million, people familiar with the matter say the joint evaluation with BMW and Samsung SDI is making solid progress. The recent decision to add a BMW executive to its board signals that the partnership is entering a critical new phase.

### Bunge Global (BG.US)

The agricultural heavyweight has recently outperformed its peers. Thanks to robust crush margins, Bunge posted a Q2 2026 net income of USD 678 million and subsequently raised its full-year outlook. However, internal discussions have flagged that future margins remain highly sensitive to shifting global biofuel policies and trade conditions.

### Bank of New York Mellon (BNY.US)

The legacy custody bank is undergoing one of its most aggressive digital pushes in years. BNY Mellon reported a record USD 5.7 billion in Q2 revenue. I'm told the company is actively working to integrate staking services into its institutional digital asset custody business and just secured a new partnership with Galaxy. Still, executives privately admit that the success of this rollout hinges on the pace of crypto regulation.

### Liberty Broadband (LBRDK.US)

Liberty Broadband has been pressing ahead with the restructuring of its core assets. Following a definitive all-stock acquisition agreement with Charter Communications, the recent earnings call heavily focused on early integration prep. I'm told the merger is expected to clear key regulatory hurdles later this year.

### Also

-   **Direxion Daily S&P 500 Bear 1X Shares (SPDN.US)**: With macroeconomic uncertainty rising, institutional funds seeking to hedge against a broader market downturn are closely monitoring the liquidity of this inverse ETF.
-   **Simplify Volatility Premium ETF (SVIX.US)**: The short-volatility trade faces new tests this week amid fluctuations in the VIX.
-   **QuickLogic (QUIK.US)**: The embedded FPGA intellectual property provider is reportedly looking to expand its customer base in low-power applications.
-   **Presidio Property Trust (SQFT.US)**: The diversified REIT is still digesting the pressure from commercial real estate valuation adjustments this year.
-   **Dermata Therapeutics (DRMA.US)**: The clinical-stage biotech firm has remained quiet recently, and I don't expect any major strategic moves before its next pipeline data readout.

*This article does not constitute investment advice.*

### Related Stocks

- [ALGN.US](https://longbridge.com/en/quote/ALGN.US.md)
- [SLDP.US](https://longbridge.com/en/quote/SLDP.US.md)
- [BG.US](https://longbridge.com/en/quote/BG.US.md)
- [LBRDK.US](https://longbridge.com/en/quote/LBRDK.US.md)
- [QUIK.US](https://longbridge.com/en/quote/QUIK.US.md)
- [SQFT.US](https://longbridge.com/en/quote/SQFT.US.md)
- [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md)

## Related News & Research

- [Bunge Global Completes $600 Million Senior Notes Offering](https://longbridge.com/en/news/296402153.md)
- [Bunge prices USD 600 million senior notes offering](https://longbridge.com/en/news/296396149.md)
- [Bunge prices $600 million senior notes offering](https://longbridge.com/en/news/296148270.md)
- [Align Technology (ALGN) Stock Looks Cheap On Cash Flow Yet Fair On Earnings](https://longbridge.com/en/news/296035484.md)
- [Liberty Broadband-Charter merger set to close Aug. 19, 2026, B3 depositary says](https://longbridge.com/en/news/296271705.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**